Goodwill and Other Intangibles
|12 Months Ended|
Dec. 31, 2017
|Goodwill and Intangible Assets Disclosure [Abstract]|
|Goodwill and Other Intangibles||
Goodwill and Other Intangibles
Changes in the Company's goodwill during the period ended December 31, 2017, by segment, are summarized below:
Changes in the Company's goodwill during the period ended December 31, 2016, by segment, are summarized below:
Adjustments in 2017 and 2016 relate to the effect of foreign currency translation on goodwill denominated in currencies other than the U.S. dollar. See Note 4 – Acquisitions for further details on the Company's acquisitions.
As of December 31 2017 and 2016, the Company had no accumulated impairment loss.
The Company's intangible assets, included within Other intangibles, net on the Consolidated Balance Sheets as of December 31, 2017 and 2016, are summarized by intangible asset type below:
The Company's intangible assets, included within Other intangibles, net on the Consolidated Balance Sheets as of December 31, 2017 and 2016, are summarized by segment below:
In the fourth quarter of 2017, the Company recorded an impairment charge relating to the Cybex trade name. Refer to Note 3 – Restructuring, Exit, Integration and Impairment Activities for further details.
Other intangible assets primarily consist of patents. See Note 4 – Acquisitions for further details on intangibles acquired during 2017 and 2016. Gross amounts and related accumulated amortization amounts include adjustments related to the impact of foreign currency translation. Aggregate amortization expense for intangibles was $8.4 million, $6.8 million and $3.0 million for the years ended December 31, 2017, 2016 and 2015, respectively. Estimated amortization expense for intangible assets is $8.6 million for the year ending December 31, 2018, $8.0 million in 2019, $7.6 million in 2020, $6.7 million in 2021, and $5.8 million in 2022.
No definition available.
The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.
Reference 1: http://www.xbrl.org/2003/role/presentationRef